An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors

Purpose: Satraplatin is a third generation oral platinum, which has demonstrated antitumor activity. The aim of this phase I study was to determine the maximum tolerated dose (MTD) of the combination of satraplatin and gemcitabine in patients previously treated with chemotherapy and in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Paola, Eugenio Donato Di, Alonso, Silvia, Giuliani, Rosa, Calabrò, Fabio, D’Alessio, Antonietta, Regine, Giovanni, Cerbone, Linda, Bianchi, Laura, Mancuso, Andrea, Sperka, Sabine, Rozencweig, Marcel, Sternberg, Cora N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2012
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504330/
https://www.ncbi.nlm.nih.gov/pubmed/23189269
http://dx.doi.org/10.3389/fonc.2012.00175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504330/
https://www.ncbi.nlm.nih.gov/pubmed/23189269
http://dx.doi.org/10.3389/fonc.2012.00175

Ejemplares similares